ASCO 2023 | Prognosis and trends in chemotherapy use for patients with stage IA TNBC

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from a study that analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the outcomes of patients with stage IA triple-negative breast cancer (TNBC) and the utilization of adjuvant chemotherapy (chemo) in this population. The study included 8,601 women, and the majority received adjuvant chemo. The use of chemo increased over time for T1b and T1c tumors, with higher utilization in 2019 compared to 2010. Variables associated with chemo use included younger age, white race, married status, higher income, more recent diagnosis, higher tumor grade, ductal histology, and larger tumor size. Adjuvant chemo was associated with improved breast cancer specific survival, particularly for T1c tumors. The study highlights the favorable prognosis of stage IA TNBC and the evolving trends in adjuvant chemo utilization. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.